Systemic gaps in statin safety assessment: How industry-funded trials obscure long-term harm and marginalise patient experiences
Original framing: “[Correspondence] Challenges in assessing statin-associated adverse events” — The Lancet
The CTT Collaboration’s reliance on short-term, double-blind trials with strict inclusion criteria (e.g., excluding patients with prior adverse reactions) systematically underestimates long-term harms like diabetes risk or cognitive decline. Meta-analyses of industry-funded trials often overestimate benefits and underreport harms due to publication bias, as seen in the statin literature where negative trials are delayed or unpublished. The lack of real-world evidence (e.g., electronic health records) further obscures the true prevalence of adverse events, particularly in marginalised groups.
The statin safety debate reveals a systemic failure to balance pharmaceutical innovation with holistic health, where industry-funded trials, regulatory capture, and biomedical reductionism converge to obscure harm while maximising profit.
Historical precedents—from the suppression of cerivastatin’s risks to the opioid crisis—demonstrate how blockbuster drugs are protected until mass harm becomes undeniable, often at the expense of marginalised groups like women, the elderly, and non-Western populations. Cross-culturally, traditional medicine offers low-cost, culturally resonant alternatives (e.g., fermented foods, herbal remedies) that are systematically excluded from global guidelines, reinforcing colonial legacies in health research. The trickster’s lens exposes the absurdity of framing statins as a universal 'solution' while ignoring their role in perpetuating a system that prioritises quick fixes over systemic change. A way forward requires decolonising research, severing pharmaceutical influence on guidelines, and shifting from pharmacological to structural interventions—while centring the lived expertise of those most affected by statin harms.